Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective curative treatment for several high-risk hematological malignancies (high-risk leukemia, myelodysplastic syndromes, advanced myeloproliferative disorders, high-risk lymphomas, and multiple myeloma). Sixty years after the first clinical application, it is currently applied in more than 15,000 patients per year in Europe [1] . The post-transplant immune restoration is one of the main factors influencing the clinical outcome of allo-HSCT. Even though fast hematopoietic engraftment and chimerism can usually be documented, severe immune defects commonly occur early after transplant and might persist for several months. The kinetics and quality of immune reconstitution depend on several pre and post-transplant variables. Well established pre-transplant parameters include the age of the recipient, diagnosis, degree of HLA antigen mismatches and non-HLA antigens, origin and manipulation of the graft, conditioning regimen, infectious serostatus of the donor and recipient. Several clinical parameters, including infectious complications, disease relapse, occurrence of graft-versus-host disease (GvHD), impaired thymic function, contribute to post-transplant immuno-incompetence [2] [3] [4] [5] [6] [7] .
Considerable efforts have been made in recent years to boost immune reconstitution with innovative transplant procedures [8, 9] and experimental cellular therapies [10, 11] . In addition post-transplant immune interventions become standard of care. In parallel, a large number of clinical studies have been devoted to identify biomarkers predictive of a fast and robust immune reconstitution and of a favorable outcome [7, [12] [13] [14] [15] . The EBMT Cellular Therapy & Immunobiology Working Party (CTIWP) conducted a survey to identify current policies to monitor immune reconstitution in patients undergoing allo-HSCT. This study followed the EBMT study guidelines. All EBMT Centers were invited to participate. Each participating Center received a questionnaire on the availability of specific immunomonitoring assays, specifying the use in clinical practice or only within investigational trials. The questionnaire was designed to cover the most used quantitative and qualitative features of Different assays were examined: complete blood count with differential; immunoglobulins; T, B and NK cell subsets; biomarkers of thymic output (T-cell receptor excision circles, TRECs, and K-deleting recombination excision circles, KRECs); hematopoietic chimerism monitoring assays (STR, qPCR, Fish); antigen-specific functional assays (T-cell proliferative responses; antibodies; responses to specific viral and tumor antigens: ELISPOT, tetramers, intracellular cytokine secretion); measures of immune diversity (spectratyping, TCR sequencing).
Descriptive statistics were utilized to analyze answers by Centers participating to the survey, as well as distribution of responses according to the questionnaire.
Responses were received from 76 participating EBMT Centers active in 22 Countries (Fig. 1a) : Algeria (1 center), Australia (2 centers), Austria (1 center), Belgium (1 center), Czech Republic (3 centers), Finland (2 centers), France (7 centers), Germany (8 centers), Greece (2 centers), Hungary (1 center), Israel (3 centers), Italy (14 centers), Netherlands (1 center), Poland (1 center), Portugal (1 center), Russia (1 center), Spain (9 centers), Sweden (3 centers), Switzerland (2 centers), Tunisia (1 center), Turkey (7 centers), UK (5 centers). This corresponds to 21.5% of the 354 full (Fig. 1a-b) ; consequently all the data analysis have been showed according to this categorization ( Fig. 1c-d) .
Of the 76 Centers, all performed allo-HSCT from HLA identical related donor, while 73 reported having performed allo-HSCT from matched unrelated donor (Fig. 1b) . Moreover, 74 centers performed allo-HSCT from haploidentical donors, and 63 from unrelated cord blood.
All Centers routinely test complete blood counts and immunoglobulins for patients' care. Other assays are handled with different policies in different Centers: when available, tests can be performed as standard-of-care, so classified as "clinical", with the possibility to use the same test also as investigational. On the contrary, some tests are used only in the context of clinical trials, and their use is thus classified as "only investigational". T cell subsets are currently tested by flow-cytometry as "standard of care" by 82% of Centers. B cell and NK cell counts are quantified by 66 and 54 Centers, routinely in 53% (n = 35) and 39% (n = 21) of them.
All Centers except three, have the availability of molecular tests (STR chimerism, qPCR, Fish) to measure posttransplant engraftment, as a standard of care assessment in 97%.
TRECs as surrogate markers of thymic function and KRECs for B-cell generation are quantified in 26 Centers (89% within selected clinical trials). Most of the participating Centers (68%) commonly test antigen-specific antibodies, mainly as responses to vaccines, and not routinely.
Interestingly, a total 66% (n = 50) of Centers evaluate, mostly as an investigational measure, antigen specific T cell responses by: proliferation assays (n = 38), interferongamma enzyme-linked immunospot-Elispot (n = 33), intracellular cytokine staining (n = 36) and tetramer/dextramer staining (n = 25). Most of these Centers test responses to Cytomegalovirus and Epstein Barr Virus, and 21 Centers use at least one of these assays on a routine basis.
T-cell receptors (TCR) and B-cell receptors (BCR) repertoires are measured by spectratyping in 29 Centers (13 as clinical practice and 16 in selected trials), or, mainly in selected trials, by next generation sequencing (in 25 of the participating Centers).
We have not observed substantial differences among various donor sources (Fig. 2a-d) . Minor changes have been registered comparing Centers by transplant volume (Fig. 1c-d) , showing a more investigational than clinical use of posttransplant immunomonitoring assays in high volume Centers.
Assessment of the post-transplant immune status is becoming a key issue and is currently monitored with different techniques in different centers, with the aim of identifying clinically relevant immunological biomarkers. Usage of the above-mentioned state-of-the art techniques allows to assess and monitor the dynamics of immune reconstitution, in particular of T-cell diversity, thymic function and antigen-specific T-cell responses following HSCT. However, it is unclear which and how many of these tests are currently performed on a routine basis, and which ones have the potential to guide patient care after allo-HSCT [12, 13] .
To our knowledge, this is the first attempt to investigate the management of post-transplant immune monitoring through the administration of a survey. The wide adoption of descriptive questions and closed answers in our survey might have contributed to reduce misinterpretation.
The low participation rate to this survey, compared to the total number of EBMT centers, could represent a risk for poor generalizability of results; nevertheless, the participating centers are clearly highly involved in post-transplant immunomonitoring and could thus lead the road in the effort of harmonizing and standardizing methods and protocols. Indeed, results of the survey in this limited sample of participating Centers indicate that country-and Center expertize are associated with heterogeneous and distinct protocols, and underline the clinical need to harmonize methods and to provide practical recommendations for monitoring post-transplant immune reconstitution.
Adequate reporting and connection between individual Centers exploiting these data will foster collaborative and comparative research studies, with the ultimate goals of improving patient care and refining our understanding of the immunological correlates to clinical outcome. Translating immune monitoring from research laboratories to clinical practice, and taking full advantage of this information to modulate post-transplant clinical events, represents a great challenge in the context of increasing regulations for laboratory medicine (such as certification by national accreditation bodies in several countries) and testing the ability to perform the different immunomonitoring assays, exchange of protocols and teaching in different laboratories, as well as an important avenue to improve the outcome of hematopoietic cellular therapies.
